Table. Characteristics of 453 Patients and Analysis of Demographic, Disease, and Treatment Variables Associated With Anti-RBD Antibody 1 Month and 3 Months After the Second Messenger RNA Vaccine Dose.
| Characteristic | No. (%) | 1 mo After second dose | 3 mo After second dose | ||||
|---|---|---|---|---|---|---|---|
| No. (n = 293) | GMT (95% CI) | GMT ratio | No. (n = 336) | GMT (95% CI) | GMT ratio | ||
| Age group, y | |||||||
| ≤50 | 89 (20) | 56 | 765.29 (306.94-1908.09) | 1 [Reference] | 60 | 716.35 (349.50-1468.25) | 1 [Reference] |
| 51-65 | 188 (41) | 131 | 557.35 (312.00-995.65) | 0.73 (0.41-1.30) | 133 | 551.42 (363.33-836.88) | 0.77 (0.51-1.17) |
| >65 | 176 (39) | 106 | 315.28 (176.68-562.60) | 0.41 (0.23-0.74) | 143 | 269.15 (176.15-411.26) | 0.38 (0.25-0.57) |
| Sex | |||||||
| Female | 253 (56) | 167 | 541.08 (325.79-898.62) | 1 [Reference] | 192 | 561.60 (393.30-801.92) | 1 [Reference] |
| Male | 200 (44) | 126 | 413.26 (235.09-726.46) | 0.76 (0.43-1.34) | 144 | 294.39 (189.92-456.31) | 0.52 (0.34-0.81) |
| Cancer type | |||||||
| Solid tumor | 319 (70) | 203 | 808.65 (544.11-1201.82) | 1 [Reference] | 244 | 547.44 (417.13-718.46) | 1 [Reference] |
| Hematologic malignant tumor | 134 (30) | 90 | 149.90 (67.77-331.58) | 0.19 (0.08-0.41) | 92 | 218.67 (108.22-441.85) | 0.40 (0.20-0.81) |
| Vaccine type | |||||||
| BNT162b2 | 273 (61) | 178 | 503.44 (318.84-794.91) | 1 [Reference] | 201 | 371.10 (267.31-515.19) | 1 [Reference] |
| mRNA-1273 | 160 (35) | 101 | 676.07 (337.90-1352.68) | 1.34 (0.67-2.69) | 122 | 553.54 (327.79-934.78) | 1.49 (0.88-2.52) |
| JNJ-7846735 | 17 (4) | 14 | 24.00 (8.31-69.34) | 0.05 (0.02-0.14) | 13 | 304.29 (74.57-1241.65) | 0.82 (0.20-3.35) |
| Treatment groupa | |||||||
| Chemotherapy | 180(40) | 114 | 609.48 (322.36-1152.31) | NA | 142 | 584.34 (392.75-869.38) | NA |
| Immunotherapy | 75 (17) | 51 | 1053.63 (537.35-2065.94) | NA | 57 | 442.74 (263.19-744.76) | NA |
| SCTb | 114 (25) | 77 | 325.35 (149.93-706.01) | NA | 78 | 454.36 (237.48-869.32) | NA |
| Chemoimmunotherapy | 21 (5) | 15 | 314.28 (71.67-1378.11) | NA | 16 | 262.98 (85.98-804.40) | NA |
| CDK4/6 inhibitors | 23 (5) | 12 | 1800.32 (580.83-5580.21) | NA | 15 | 1099.05 (459.09-2631.11) | NA |
| TKIsc | 32 (7) | 19 | 189.84 (54.86-656.91) | NA | 20 | 157.56 (56.51-439.36) | NA |
| Oral (other agents)d | 8 (2) | 5 | 1.73 (0.10-30.58) | NA | 8 | 3.31 (0.22-48.78) | NA |
Abbreviations: anti-RBD, anti–SARS-CoV-2 spike protein receptor binding domain; CDK, cyclin-dependent kinase; NA, not applicable; SCT, stem cell transplant; TKIs, tyrosine kinase inhibitors.
a
The geometric mean titers (GMTs) of individual treatment groups are included. Given the small numbers in some of the treatment categories, the GMT ratios for comparison are not shown.
b
Allogeneic SCT, Autologous SCT, and chimeric antigen receptor T-cell therapy.
c
Only 1 patient among the TKI treatment group in this analysis had a hematologic malignant tumor.
d
This category included 5 patients with chronic lymphocytic leukemia receving venetoclax and 2 patients receiving non-TKI, non-CDK4/6 inhibitors.